The results paint a stark comparison between now and the feelings and concerns that existed a year previously.
The survey, in which 80% of respondents are from businesses that employ 250 people or fewer, showed the following:
EMIG is a multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK. Its industry members range from new business start-ups focused on R&D, through to well-established companies delivering a wide range of essential medicines to patients. Its members supply 50% of branded medicines by volume to the NHS.
It is not surprising that pharma has spent a lot of money preparing for Brexit, nor that there has been a big increase in feelings of a 'no-deal' Brexit, given the failure to agree anything in the spring and change in government.
Through PING (Pharmaceutical Industry Network Group), VWV held a sell-out conference in association with EMIG, on 3 April 2019, on how Brexit has affected the pharma supply chain. We heard about regulatory, research, immigration and trade issues; as well as an interesting and uplifting perspective from a European-based industry speaker. Press coverage of the event can be found in PharmaTimes and Pharmafield.